17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
Results from the Phase IIa SATELLITE trial demonstrated that AZD4831, a myeloperoxidase (MPO) inhibitor, achieved pre-specified target engagement in patients with heart failure with preserved ejection fraction (HFpEF), supporting the further development of this novel therapy. 1 July 2021
Merlin Piscitelli, chief revenue officer for EMEA at Datasite, provides an Expert View on M&A trends and predictions for deal-making in life sciences, and some of the challenges we may expect. 1 July 2021
Despite one multi-billion deal and another worth $1.7 billion, the summer break seemed to come early in the pharmaceutical M&A market this year, with precious few companies in acquisitive mode during May and June. 30 June 2021
A group of five of India’s major pharmaceutical companies are to collaborate on a trial of the investigational oral anti-viral drug molnupiravir for the treatment of mild COVID-19 in an outpatient setting. 30 June 2021
The US Food and Drug Administration (FDA) yesterday published a report titled “Assessment of the Use of Patient Experience Data in Regulatory Decision-Making.” 30 June 2021
Virtual clinical development specialist Phesi has published a new data analysis on growth in recruiting clinical trial sites in China since the beginning of 2018. 29 June 2021
Adding to a string of distribution deals, UK specialty pharma firm Diurnal Group (AIM: DNL) says it has extended its distribution arrangements with Er-Kim. 29 June 2021
UK pharma major GlaxoSmithKline and French peer Servier have reached an agreement for increase the production of dolutegravir, which is a drug for the treatment of HIV at the facilities of Servier RUS plant in Moscow, according to recent statements by the press service of the Department of Investment and Industrial Policy of the Moscow city government. 29 June 2021
US healthcare giant Johnson & Johnson is to pay $230 million to the state of New York in a settlement over accountability for the opioid epidemic ahead of a court case due to begin this week. 28 June 2021
For Dravet Syndrome Awareness Month (June), we explore advances in pharmacological treatments for this rare, drug-resistant epilepsy that is characterized by prolonged seizures and fevers that affect one side of the body.1 28 June 2021
Danish diabetes care giant Novo Nordisk has presented data showing that an investigational 2.0mg dose of Ozempic (semaglutide) provided statistically-significant and superior reductions in blood sugar (HbA1C) compared with Ozempic 1.0mg. 28 June 2021
Eli Lilly has announced that results from the SURPASS-2 study have been published in The New England Journal of Medicine, showing that its investigational drug tirzepatide achieved superior HbA1C and weight reductions compared to semaglutide in people with type 2 diabetes. 26 June 2021
A new report has claimed that rapid advances in therapy innovation, process technologies and macro changes will deliver a post-pandemic surge across the US pharma industry. 25 June 2021
The pharmaceutical industry in Paraguay – comprising of domestic drugmakers and multinationals with a presence in the country – is expected to grow by at least 5% in 2021, writes The Pharma Letter’s Latin American correspondent. 25 June 2021
The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of privately-held Danish drugmaker Leo Pharma by Nordic Capital Fund X of Jersey and Leo Foundation of Denmark. Leo Pharma develops, manufactures and markets pharmaceutical products. 25 June 2021
Gilead Sciences has announced interim results from Phase IIb and Phase III trials evaluating Hepcludex (bulevirtide), a first-in-class treatment for chronic hepatitis delta virus (HDV). 24 June 2021
The US subsidiary of Japanese ophthalmology specialist Santen Pharmaceutical today announced that the US Food and Drug Administration has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. 24 June 2021
Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted regulatory approval for Evrysdi (risdiplam) Dry Syrup 60mg for the treatment of spinal muscular atrophy (SMA). 24 June 2021
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.